Page 1

= MEDIOS Press Release Medios AG : Successful financial year 2020 ● Significant sales growth in 2020 - strong fourth quarter Outlook 2021 : Sales expected to almost double to up to € 1.2 billion and earnings to increase significantly in 2021 Focus on further acquisitions , digitization and sustainability Berlin , March 31 , 2021 – Medios AG ( " Medios " ) , the leading provider of Specialty Pharma solutions in Germany , has published its Annual Report 2020. In the reporting year 2020 , group sales increased by 21.2 % to € 626.5 million ( previous year : € 516.8 million ) compared to the same period of the previous year , thus reaching a record level despite a difficult market environment . However , due to the COVID 19 - related effects , consolidated earnings did not reach the previous year's level : Consolidated earnings before interest , taxes , depreciation and amortization ( EBITDA ) * adjusted for extraordinary expenses amounted to € 15.1 million ( previous year : € 17.7 million ) and consolidated earnings before taxes ( EBT ) * adjusted for extraordinary expenses were around € 12.0 million ( previous year : € 16.2 million ) . Medios carried out , or prepared , two forward - looking acquisitions in the year under review : Kölsche Blister GmbH expanded the company's business model to include the attractive service of blister packaging . With the acquisition of the specialized pharmaceutical wholesaler Cranach Pharma GmbH , which has since been completed , Medios has significantly strengthened its position as a full - range supplier in the Specialty Pharma segment . For the current fiscal year , Medios expects a significant increase in sales , for the first time exceeding one billion , to € 1.2 billion , as well as a substantial jump in earnings . Both operating segments with dynamic sales growth The Pharmaceuticals Supply business segment achieved sales growth of 21.1 % to € 564.3 million in fiscal 2020 ( previous year : € 466.1 million ) . The main reasons for the strong growth were the further expansion of the partner network and the expansion of the product range , including the hemophilia indication area launched in September 2020. Adjusted EBITDA * for the segment declined by 19.1 % to € 9.6 million ( previous year : € 11.9 million ) and adjusted EBT * fell by 27.2 % to € 8.2 million ( previous year : € 11.2 million ) . This segment result in particular was burdened by Corona - related effects , such as higher procurement costs . The Patient - Specific Therapies business segment generated sales of € 61.9 million in fiscal 2020 , an increase of 22.7 % over the previous year ( previous year : € 50.4 million ) . This was due in particular to the significant increase of individualized manufacturing units to over 100,000 in 2020 and the further diversification of the indication areas .